SORLA Protein Reduced Brain Damage in Mouse Study
Researchers found that increasing this protein may help protect the brain from tau-related damage.
Updated on Sept. 19, 2026 in Alzheimer’s
Live Poll
Do you believe current protein-based research is likely to yield successful Alzheimer's treatments soon?
A study published on July 17, 2026, in Science Advances found that increasing SORLA protein levels reduced tau accumulation and brain atrophy in mice. This research suggests a potential new path for addressing tau tangles in neurodegenerative conditions.
Why it matters
Understanding how SORLA affects tau proteins is vital for developing future treatments, as researchers previously knew this protein impacted amyloid-beta but sought to clarify its wider role in dementia pathology.
In a preclinical study published in Science Advances, researchers found that mice engineered to produce extra human SORLA experienced reduced brain atrophy and preserved synapses. The results confirm that SORLA suppresses tau hyperphosphorylation, though these findings remain in mouse models.
The players
Sanford Burnham Prebys
A biomedical research institute where the investigators conducted this study on neurodegenerative mechanisms.
The details
To investigate the role of SORLA, scientists modified mice to lack the Sorl1 gene, which led to increased brain damage and elevated levels of plexin-B receptors. By producing extra SORLA, the researchers successfully mitigated these effects, suggesting that the protein acts as a protective mechanism against tau tangles. The team is now looking into whether drugs targeting plexin-B receptors could provide a viable treatment approach for tau-related dementia.
Timeline
July 17, 2026: The study was published in Science Advances.
Health Landscape
This research builds upon decades of study into the SORLA protein and its function in maintaining brain health. It shifts the scientific focus toward how protein regulation might address tau pathology, a critical component of neurodegeneration that remains a major hurdle in clinical care.
Because this study was conducted in mice, the results do not yet affect current clinical practices for patients in San Diego. It is worth discussing the evolving science of protein-based therapies with your neurologist to understand how research into tau pathology might influence future care options.
The takeaway
This study highlights the protective role that the SORLA protein may play in preventing tau accumulation in the brain. Patients and caregivers should continue to track developments in clinical research, as ongoing trials and studies help clarify how such laboratory findings translate to human therapy.
Further reading
For more on the latest research developments, explore our Alzheimer’s section.
More information
View the complete Science Advances study publication for full methodology.
Live Poll
Do you believe current protein-based research is likely to yield successful Alzheimer's treatments soon?
